Strengthening detection, prevention and response to infectious disease threats in Uzbekistan

archived

Currently the Research Institute for Epidemiology, Microbiology and Infectious Diseases of the Ministry of Health of the Republic of Uzbekistan (RIEMID) is concluding activities under CDC Co-Ag GH001653 focused on antimicrobial resistance. RIEMID is designated to be the Center of genetic technologies by the Presidential Decree PP-4790 dated July 27, 2020. In this regard, CDC would like to work with RIEMID on non-research activities, including establishing a Center for Genome Sequencing of Emerging, Re-Emerging Infectious Diseases by 1) providing training and mentorship to the staff at the Center, 2) purchasing specialized gene sequencing equipment, 3) sharing established methodologies for sequencing of pathogens, 4) analyzing sequencing data, and 5) showing the relevance of sharing data with the global community. This Center would increase the capacity of Uzbekistan to detect, investigate, and report COVID-19 transmission. Uzbekistan will have the ability to recognize new strains or mutations of strain of SARS-CoV-2. Sequencing data would give the country (and others if shared) a deeper understanding of pathogen phylogeny, which can assist in vaccine production. In addition, CDC would like RIEMID to continue working on AMR surveillance, particularly extend it to the whole country, conduct non-research activities on strengthening the rational use of antimicrobials in the country, introduce genetic surveillance and new systems of rapid identification of bacteria (MALDI-TOF), improve quality of AMR data by assisting implementation of QMS in the bacteriology laboratories and consolidating the AMR data in RIEMID AMR reference center.

High